IL1B and COVID-19: These patients all showed evidence of hyperinflammation with raised inflammatory markers and CRP and were given anakinra i.v., with safe and successful use, suggesting the potential benefit of IL-1 blockade in this subgroup of patients with confirmed COVID-19.